Substrate deprivation therapy in juvenile Sandhoff disease

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders.
• Substrate deprivation therapy is effective for Gaucher disease but less studied in Sandhoff disease.
• Sandhoff disease results from mutations in the HEXB gene, leading to decreased hexosaminidase activity.

Observation:

• A patient with juvenile Sandhoff disease presented with epilepsy, motor, and speech regression.
• After initial stabilization, the patient experienced neurological deterioration including ataxia and muscle weakness at age 14.
• Treatment with miglustat, a glucosylceramide synthase inhibitor, was initiated.

Findings:

• Miglustat therapy stabilized the patient's neurological condition over two years, preventing further regression in motor skills, ataxia, and intelligence.
• Subjective improvements in fine motor skills and stair climbing were noted.
• No significant change in quality of life score was observed, but the patient's condition did not worsen.

Implications:

• Miglustat demonstrates potential as a therapeutic option for Sandhoff disease, a rare lysosomal storage disorder.
• This case highlights the importance of early diagnosis and intervention in managing progressive neurological decline in LSDs.
• Further research is warranted to explore the long-term efficacy and broader applicability of substrate deprivation therapy in Sandhoff disease.